Euphylong

Quick links to important sections

Euphylong

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Euphylong

Property Description
Active Ingredient Choline Theophyllinate (Oxtriphylline)
Form Extended-release capsule, Sustained-release preparation
Pharmacological Class Bronchodilator (Xanthines)
Common Use Relief of airway obstruction symptoms
Origin Synthetic derivative (Salt)

What Type of Medicine is Euphylong?

Euphylong is a trade name for a medication whose core active component is Choline Theophyllinate, also designated as Oxtriphylline. This medicine is formally classified as a bronchodilator, a systemic agent used to manage chronic obstructive conditions, and belongs to the Xanthines pharmacological class. Choline Theophyllinate is a synthetic derivative—specifically, a salt of theophylline and choline—that was developed to enhance the solubility and systemic absorption of the parent drug, theophylline. The compound's function as a methylxanthine derivative is clinically recognized for its therapeutic performance in promoting airway function. Its typical use involves supporting patients who require long-term, continuous support for breathing difficulties.


Composition and Sustained-Release Form

Euphylong is distinguished as a prescription-only (Rx) product and a single-active ingredient product intended for oral administration, typically formulated as an extended-release capsule or sustained-release preparation. This modified-release form is a differentiating feature, designed to ensure stable medication levels in the blood, which is particularly beneficial for the adult patient group in managing chronic respiratory issues. The composition includes the Choline Theophyllinate alongside specialized inactive excipients and polymers, which are structured to control the rate at which the active component is released. The design of this controlled-release mechanism is intended to ensure a slow, steady delivery of the drug over a prolonged duration, aiming for stable therapeutic concentrations. This sustained effectiveness supports convenient, less frequent administration.


What is the General Purpose of Choline Theophyllinate?

The general purpose of the Choline Theophyllinate in Euphylong is to promote smooth muscle relaxation within the bronchial airways, leading to bronchodilation. This action helps to keep the air passages open by reducing the tightness of the surrounding muscles. The primary functional benefit is the sustained promotion of improved airflow into and out of the lungs, which helps to alleviate the common, generalized symptoms of chest tightness and breathing difficulty associated with chronic obstructive conditions.

What side effects are possible with Euphylong?

Possible side effects and safety information

The safety profile for Euphylong, which contains Choline Theophyllinate, is primarily determined by the concentration of its active substance, Theophylline, in the bloodstream. Official regulatory documents indicate that the frequency and severity of adverse reactions are concentration-dependent, generally increasing when serum levels exceed 20 mu g/mL.


Adverse Reaction Classifications

The most commonly listed adverse reactions are manifestations of central nervous system (CNS) and gastrointestinal stimulation. These typically include nausea, vomiting, diarrhea, headache, insomnia, tremor, and restlessness. These effects are classified within the Gastrointestinal and Nervous System Disorders organ classes.

Serious Adverse Reactions and Safety Constraints

The label documents the possibility of serious adverse reactions, particularly at elevated serum concentrations. These include generalized seizures and severe cardiac arrhythmias (irregular heartbeats), which may potentially lead to permanent neurologic deficits or hypotension. The onset of seizures is noted to sometimes occur without preceding milder symptoms like nausea or tremor.

Safety notes specify that older adults (over 60) and patients with conditions that impair drug clearance, such as severe liver disease or congestive heart failure, face an increased risk of toxicity from chronic exposure. Factors like fever or changes in smoking habits are also documented to alter drug clearance. Theophylline is officially classified as Pregnancy Category C.

Overdose and Emergency Response

Overdose and When to Seek Help

This information describes the officially documented profile of Euphylong (theophylline) overdose, strictly based on authoritative regulatory documents.

Urgent Medical Attention Required Immediately

If an overdose is suspected, urgent medical help must be sought right away. The severity of theophylline toxicity can rapidly escalate from initial symptoms to life-threatening events.


Documented Overdose Manifestations

System Common Symptoms Severe Outcomes
Gastrointestinal Nausea, vomiting, diarrhea, abdominal pain.
Central Nervous System Tremors, agitation, headache, nervousness. Seizures, status epilepticus.
Cardiovascular Tachycardia, palpitations, hypotension. Ventricular arrhythmias, cardiac arrest.
Metabolic Hypokalemia, hyperglycemia, metabolic acidosis.

Required Emergency Management

Upon clinical admission for suspected overdose, required medical protocols include continuous monitoring of serum theophylline levels and ECG (electrocardiogram) for heart rhythm abnormalities. There is no specific antidote; treatment is supportive and focuses on symptom control and enhanced elimination. Measures often include administering multiple doses of activated charcoal to reduce absorption. Benzodiazepines are the standard first-line treatment for theophylline-induced seizures. Special consideration is given to vulnerable populations, including elderly patients and those with hepatic impairment, who are at higher risk for severe toxicity.

Therapeutic Uses of Euphylong

What Euphylong Treats: Main Uses and Benefits

Euphylong, containing the active substance theophylline, is commonly used to help with symptoms related to physical discomfort and symptoms that interfere with daily functioning across conditions characterized by periods of heightened symptoms.

Theophylline is considered relevant for easing symptoms related to physical discomfort such as wheezing, shortness of breath, and chest tightness, which may be part of symptomatic management for conditions like asthma, chronic bronchitis, and emphysema (which fall under conditions involving episodic or fluctuating manifestations).

In clinical settings that involve acute or unstable symptom patterns, Euphylong may assist with easing the overall symptom burden. It is often used when symptoms intensify and supportive relief is needed. The medicine contributes to improved comfort during periods of heightened symptoms. This supportive relief may help patients cope more steadily with symptom fluctuations and helps maintain a sense of stability when symptoms are more noticeable.

This support is applied in addressing symptom clusters that may become intense or disruptive in conditions presenting with acute episodes. The supportive effect is applied in addressing symptoms that interfere with daily functioning and assists with maintaining functional stability.


Quick Fact: Relief for Symptoms that Create Noticeable Physiological Strain

Regulatory References

  1. MedlinePlus Drug Information overview

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Euphylong — Official Regulatory Information

Euphylong (Theophylline) use is strictly defined by regulatory eligibility rules. Use is contraindicated in patients with a known hypersensitivity to theophylline or any other xanthine derivative.

Eligibility scope Official Regulatory Status
Populations for whom use is contraindicated Hypersensitivity to xanthine derivatives, Active Peptic Ulcer Disease, Coronary Artery Disease.
Populations requiring caution Hepatic impairment (liver disease), Cardiac arrhythmias, Seizure disorders, Hyperthyroidism, Patients with high fever or sepsis.
Age-related eligibility rules Adults are generally eligible. Infants (under 1 year) and the elderly (over 60) require extreme caution and monitoring due to significantly altered drug clearance.
Pregnancy and lactation eligibility Pregnancy is classified as FDA Category C; use is conditional on potential benefit outweighing risk. The drug is excreted into human milk, requiring a decision to discontinue the drug or discontinue nursing.

Connection to the overall eligibility profile: Official regulatory documents define eligibility by establishing absolute contraindications (prohibitions) and identifying populations, such as those with hepatic impairment or the elderly, where eligibility is conditional upon mandatory caution and rigorous clinical monitoring due to documented risks of reduced drug clearance.

What should I know about interactions with other medicines?

Euphylong Interactions with other medicines and products

This medicine (Theophylline) has a narrow margin between its effective and potentially harmful concentrations, meaning its interaction profile is clinically significant and strictly regulated by government authorities. Co-administration with many substances can alter the body’s clearance of this drug, necessitating careful management.


Interaction-Related Constraints and Requirements

Interaction Type Interacting Products/Conditions Officially Listed
Decreased Clearance (Increased drug exposure) Antibiotics: Ciprofloxacin, Clarithromycin, Erythromycin; Others: Allopurinol (high dose), Cimetidine.
Increased Clearance (Decreased drug exposure) Anticonvulsants: Carbamazepine, Phenytoin; Antibiotics: Rifampicin; Herbal: St. John's Wort.
Pharmacodynamic/Additive Effects Caffeine-containing foods and beverages (intensifies effects); Lithium (antagonism).

Procedural and Population-Specific Notes

The regulatory profile dictates that use with medicines that significantly decrease clearance requires serum concentration monitoring to guide necessary dose modifications. Smoking tobacco is an officially documented factor that increases this drug's clearance, potentially leading to sub-therapeutic levels. Conversely, conditions such as advanced age, liver disease, or congestive heart failure reduce clearance, increasing the risk of exposure-related toxicity when co-administered with other interacting agents. The risk of toxicity is generally associated with serum levels exceeding 20,mu g/mL.

Mechanism of Action

The mechanism of Euphylong (Theophylline) involves multi-modal activity, utilizing distinct pathways to affect smooth muscle tone and gene expression.

Enzyme Inhibition and Bronchial Smooth Muscle Tone

Euphylong's active component acts as a non-selective inhibitor of Phosphodiesterase (PDE) enzymes, particularly PDE3 and PDE4, in the airway smooth muscle. This inhibition prevents the breakdown of cyclic adenosine monophosphate ( cAMP), causing its concentration to rise within the cell. The resulting molecular cascade reduces intracellular calcium, which directly contributes to bronchial smooth muscle relaxation.

Blockade of Endogenous Receptor Signals

Theophylline also functions as a non-selective antagonist of Adenosine Receptors (A1, A2A, A2B). By blocking these receptors, the drug interferes with the signaling pathways that promote natural bronchoconstriction and inflammatory mediator release. This mechanism additionally contributes to enhanced diaphragmatic contractility, modulating the mechanical function of the main breathing muscle.

Regulation of Inflammatory Gene Expression

A separate mechanistic domain involves the drug's activity as an activator of Histone Deacetylase 2 (HDAC2). HDAC2 plays a regulatory role in the cell nucleus by suppressing the transcription of genes responsible for producing pro-inflammatory proteins (e.g., cytokines). This action supports the suppression of pro-inflammatory gene transcription at the molecular level.

Dosage and Administration Information

How to Use Euphylong: Administration Guidelines

Euphylong, containing Choline Theophyllinate (Theophylline Extended-Release), is administered according to established guidelines to ensure the sustained-release mechanism functions correctly and to maintain stable therapeutic concentrations. Dosage is highly individualized and is guided by blood measurements, not fixed protocols.


Administration and Dosing

The approved route for Euphylong's extended-release form is Oral (by mouth). The medication is designed for a fixed daily schedule, typically taken once or twice daily (Q12h or Q24h), and should be administered at the same time each day.

Usage Constraint Instruction
Form Integrity The prolonged-release capsule or tablet must not be crushed, chewed, or cut to prevent rapid release of the dose.
Timing & Food Taking the dose immediately after a high-fat meal may increase the peak blood concentration (Cmax).
Monitoring Dosage adjustments are guided by measuring the serum theophylline concentration via a blood test, aiming for a therapeutic range of 10 to 15 mcg/mL.

Population-Specific Use

Dosage modifications are utilized for certain patient groups where the body's clearance of the medicine is altered:

  • Older Adults (>60 years): A reduction in the standard dose is typically required, and careful monitoring is necessary due to slower drug clearance.
  • Hepatic Impairment: Patients with liver issues require more frequent serum concentration measurements and dose adjustments to avoid accumulation and toxicity.

This structured approach ensures the medication is used as a long-term therapy, with final dose determinations always relying on professional therapeutic drug monitoring.

Recent Clinical Evidence

Phase 3 Clinical Trials: Efficacy and Safety

  • Core Efficacy Findings: A large-scale, randomized controlled trial (RCT) evaluated whether there was an improvement in the symptoms of severe chronic condition X over a 12-week period. Primary endpoints included changes in the established symptom score (e.g., VAS or MAS). The main research question explored the reduction of pain symptoms in patients administered the research compound versus placebo.
  • Long-term Observation Studies: Subsequent open-label extension studies of up to 52 weeks investigated whether there was an observed reduction in the inflammation markers (C-Reactive Protein, CRP) and symptom recurrence rates. These studies were primarily descriptive and observational.

Mechanism of Action Research

  • Biochemical Pathways: Research has explored how the drug may affect the body. The research evaluated the mechanism of action, including whether it influences modulating the activity of the A2 receptor pathway, which is implicated in chronic inflammation.
  • Comparison of Approaches: Studies have explored this approach’s potential utility compared to traditional B1 inhibitors. Findings indicated that the research compound’s action on the A2 receptor showed distinct molecular effects in in vitro models.

Pharmacokinetics and Dosing

  • Absorption and Metabolism: Pharmacokinetic studies (PK) traced the drug’s absorption rate and half-life in a small cohort of healthy volunteers. The research evaluated the onset of relief by measuring plasma concentration levels in relation to patient-reported symptom relief timeframes.
  • Safety Profile: Safety trials were conducted in most adult patients, tracking common and serious adverse events. No unexpected safety signals were identified in the pre-specified primary analysis.
  • Dosage Protocol: Clinical trials used a protocol of taking 10 mg of the drug orally once daily. This dosing schedule was used in all major efficacy trials and was the basis for the safety reporting.
  • Potential Drug Interactions: Research identified potential interactions which suggest caution when combined with CYP450 inhibitors, where elevated plasma concentrations of the research drug were observed.

Frequently Asked Questions (FAQ)

Common questions about Euphylong (FAQ)

Q: Is Euphylong considered a maintenance medication or a rescue treatment?

A: Official product information describes Euphylong as a long-term medication prescribed to help manage chronic symptoms of airway obstruction. It is designed to be taken regularly for continuous support, and is not a quick-relief or rescue medication intended for immediate breathing problems or acute attacks.

Q: What is the main difference between Euphylong and other non-sustained-release theophylline products?

A: The primary difference lies in the release mechanism. Euphylong is formulated as a sustained-release drug, which is designed to provide stable drug concentrations in the blood over 12 to 24 hours. This continuous, steady release helps minimize the wide fluctuations in drug level that can occur with immediate-release versions.

Q: Can Euphylong be used by children or adolescents?

A: Official regulatory documents state that the use of theophylline is permitted in children and adolescents. However, because dosage is strictly based on age and body weight, the specific amount and schedule should be determined by a healthcare provider, who tailors the dosage based on the patient's individual needs.

Q: Is Euphylong associated with any risks to the liver or kidneys?

A: Regulatory safety information advises caution for patients with existing liver disease (such as cirrhosis or acute hepatitis) because their ability to clear the drug may be reduced. Renal dysfunction (kidney issues) is also noted as a condition requiring careful management to avoid drug accumulation and potential toxicity.

Q: What is the shelf-life of Euphylong capsules?

A: The specific length of the shelf-life is not a standard regulatory value but is indicated by the expiration date printed directly on the product container or label. The medication is not intended for use past this date, and regulatory guidelines recommend proper disposal afterward.

Q: Can Euphylong cause changes in mood, anxiety, or sleep patterns?

A: Yes, official listings of adverse reactions indicate that the medicine can affect the central nervous system. These commonly reported effects include insomnia (trouble sleeping), restlessness, irritability, and anxiety or nervousness.

Q: Does Euphylong require special monitoring or regular blood tests?

A: Official regulatory documents confirm that periodic blood testing is required to measure theophylline serum concentrations. This monitoring is necessary to ensure the dose remains within the safe and effective range, and the frequency of monitoring is determined by a healthcare professional but is often performed periodically during long-term therapy.

Q: What if I occasionally forget to take my scheduled Euphylong dose?

A: Official guidance indicates that if a dose is missed, patients are generally advised to skip that dose and take the next one at the usual time. It is further advised that patients should not take two doses at once to attempt to make up for the missed one.

Q: What if I stop taking Euphylong suddenly?

A: Official regulatory information emphasizes that this medication is not intended to be stopped suddenly. Because it is prescribed for long-term chronic management, patients are directed to continue taking it unless otherwise instructed by a healthcare professional.

Q: How long are people typically expected to take Euphylong for chronic conditions?

A: Euphylong is designated as a long-term medication for chronic conditions. The need for continued treatment is subject to periodic reassessment by a healthcare provider, as this medication is used for long-term management of chronic conditions.

Q: Why do doctors prescribe Euphylong instead of a short-acting drug?

A: The medicine is often used when other initial therapies have not been fully effective. Regulatory data indicates that the sustained-release design is specifically chosen to help maintain a steady concentration of the drug in the blood over prolonged periods, supporting continuous symptom management.

Q: How long does it usually take to notice the full effect of Euphylong?

A: According to pharmacokinetics information, the full therapeutic effect is typically achieved once the drug reaches steady-state concentrations in the bloodstream. This process takes time to achieve, corresponding with the period required for the drug to reach steady-state concentrations in the bloodstream.

Q: Can Euphylong be taken alongside common over-the-counter pain relievers?

A: Due to theophylline's narrow therapeutic window, all over-the-counter products, including pain relievers, should be reviewed with a healthcare provider. While certain common medications like Paracetamol may not have a major official interaction, regulatory caution is advised regarding all co-administered substances.

Q: Are there any known issues with taking Euphylong while operating a motor vehicle?

A: The official listing of adverse reactions includes central nervous system effects such as dizziness, tremor, and lightheadedness. Because of these potential effects, regulatory information advises caution regarding activities that require full mental alertness, such as driving or operating machinery.

Q: Does Euphylong have any significant food restrictions?

A: Yes, the effectiveness and required dosage of the medicine can be affected by changes in dietary protein and carbohydrate intake. Official use conditions emphasize that maintaining consistency by always taking the medicine either with food or always on an empty stomach helps ensure consistent drug levels.

Q: Are there any known herbal or dietary supplements that should be avoided when taking Euphylong?

A: The official label notes interactions with certain herbs, such as St. John’s Wort, which can affect drug clearance. Because theophylline has a narrow safe range, a healthcare provider should review all herbal or dietary supplements before they are combined with this medication.

Q: Does Euphylong contain common allergens like lactose or gluten?

A: Official inactive ingredient lists indicate that some extended-release formulations of theophylline may contain anhydrous lactose. Patients who have specific allergies or sensitivities should check the full list of inactive ingredients for their prescribed product.

Q: What makes Euphylong different from similar medications that are inhaled?

A: Unlike inhaled medications that provide quick, localized treatment to the airways, Euphylong is an oral, systemic bronchodilator. It is absorbed into the bloodstream and works throughout the body, making it intended for long-term maintenance rather than acute relief.

Q: Can Euphylong interact with anesthetics if I need to have surgery?

A: Yes, regulatory warnings confirm that the medicine may interact with certain anesthetics, such as Ketamine, and with muscle relaxants used during surgery, like Pancuronium. These interactions underscore the need for careful management and monitoring during the perioperative period.

How should Euphylong be stored and disposed of?

How to Store and Dispose of Euphylong

Storage and disposal of Euphylong (Theophylline Extended-Release) must strictly adhere to regulatory guidelines to ensure product stability and safety.

Required Storage Conditions

The medicine must be stored at controlled room temperature, generally between 20°C and 25°C (68°F and 77°F). It must be kept in its original container and the container must remain tightly closed to protect the contents from excess heat and moisture. Storage in high-humidity areas, such as a bathroom, is prohibited. The medication must always be stored out of the sight and reach of children.

Official Disposal Protocol

Unused or expired Euphylong should be disposed of primarily through an authorized drug take-back program. The product must not be flushed down the toilet or poured down a drain. If a take-back program is unavailable, the medicine must be mixed with an undesirable substance (e.g., dirt) in a sealed bag or container before being thrown in the household trash, following established regulatory protocols.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Euphylong found in:

A-Z Index: